BRII-B

2137.HK opened at HK$1.050 and quickly dropped to an intraday low of HK$0.960 during the morning session before recovering slightly to HK$1.000, down 4.76% from the previous close of HK$1.050. The main catalyst was the company's announcement of topline end-of-treatment data from the Phase 2b ENRICH and ENHANCE studies for chronic hepatitis B, which was overshadowed by an ongoing arbitration with Vir that clouds the future of the elebsiran program. Financially, Q4 2025 revenue grew 30.02% YoY to HK$19.2 million, while net loss narrowed 65.76% to HK$41.5 million, reflecting cost control but failing to offset sentiment. The stock trades 60.63% below its 52-week high of HK$2.54 and sits below both the MA20 (HK$1.026) and MA60 (HK$1.153), indicating a weak technical position. Though the YTD decline of 29.58% suggests some oversold conditions, and the recently launched HK$60 million buyback program provides a floor.

Brii Bio shares rose 5.0% to HK$1.05 in the morning session, recovering from an intraday low of HK$1.00 to a high of HK$1.05, driven by positive end-of-treatment data from the Phase 2b ENRICH and ENHANCE studies for chronic hepatitis B. Revenue in Q4 grew 30.02% YoY to HK$19.21 million, with net loss narrowing 65.76% to HK$41.45 million, underscoring operational improvement. Yet the stock remains 58.66% below its 52-week high of HK$2.54 and below the 60-day MA at HK$1.169, with a YTD decline of 26.06%, as concerns over the arbitration with Vir regarding the elebsiran program persist.

2137.HK opened lower and fell during the morning session, dropping 5.6% from HKD 1.07 to HKD 1.01, primarily due to the disclosed arbitration outcome with Vir, which cast uncertainty on the future of core drug candidate elebsiran, despite the concurrent release of positive topline end-of-treatment results from Phase 2b ENRICH and ENHANCE studies. Financially, Q4 2025 revenue grew 30% YoY to HKD 19.21 million, while net loss narrowed 65.8% to HKD 41.45 million, with EPS improving to -HKD 0.0576, signaling a clear fundamental improvement. However, the stock remains over 60% below its 52-week high of HKD 2.54, trades below both the 20-day MA (HKD 1.021) and 60-day MA (HKD 1.182), and is down 28.9% YTD, indicating that the market is more sensitive to downside risks.

Brii Bio opened higher and surged to HK$1.100 in the morning session, but retreated in the afternoon to close at HK$1.070, up 2.88% from the previous close of HK$1.040, with a turnover of 333,000 shares and a turnover rate of only 0.05%. The intraday volatility was primarily driven by the release of topline end-of-treatment data from the Phase 2b ENRICH and ENHANCE studies for chronic hepatitis B on July 1, which triggered an initial positive reaction, but momentum faded after midday as the market weighed the arbitration with Vir that clouds the future of the elebsiran program. Financially, Q4 2025 operating revenue of HK$19.2 million grew 30% YoY, while net loss narrowed 65.76% to HK$41.5 million, with EPS of -HK$0.0576 and a net profit margin of -215.76%. The stock is 57.87% below its 52-week high of HK$2.54, 16.3% above the 52-week low of HK$0.92, and trades below the MA60 of HK$1.188 but above the MA20 of HK$1.02. However, the HK$60 million share buyback program announced earlier failed to sustain the rally, as short-term profit-taking emerged.

Brii Bio opened lower and declined steadily in the morning session, closing at HK$1.08, down 5.3% from the previous close of HK$1.14, with a single-day range from a high of HK$1.16 to the low. The decline was primarily driven by the release of end-of-treatment data from Phase 2b ENRICH and ENHANCE studies for chronic hepatitis B, alongside an arbitration with Vir that clouds the future of the elebsiran program. While Q4 2025 revenue rose 30% YoY to HK$19.2 million and net loss narrowed 65% YoY to HK$41.5 million, the stock remains 57% below its 52-week high of HK$2.54 and below its 60-day MA of HK$1.206, with a YTD decline of 24%. However, the company's HK$60 million share buyback and AI collaboration with OpenBench may offer some support.